Sio Gene Therapies to Participate in Upcoming Conferences
Sio Gene Therapies Inc. (NASDAQ: SIOX) announced its participation in several upcoming investor and scientific conferences. CEO Pavan Cheruvu will present at the Cantor Fitzgerald Global Healthcare Conference on September 27 at 10:00 AM ET and at the Chardan Genetic Medicines Conference on October 5 at 9:00 AM ET. The company will also be represented by Parag V. Meswani at the Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa on October 12, with an on-demand presentation available. Sio focuses on developing gene therapies for neurodegenerative diseases.
- None.
- None.
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will participate in select upcoming investor and scientific conferences. Details can be found below.
Cantor Fitzgerald Global Healthcare Conference
| Participation: | Presentation |
| Presenter: Date: Time: Webcast Link: | Pavan Cheruvu, MD, Chief Executive Officer Monday, September 27th 10:00 AM ET https://wsw.com/webcast/cantor12/siox/2117150 |
Chardan Genetic Medicines Conference
| Participation: | Presentation |
| Presenter: Date: Time: Webcast Link: | Pavan Cheruvu, MD, Chief Executive Officer Tuesday, October 5th 9:00 AM ET https://wsw.com/webcast/chard9/siox/1887025 |
Alliance for Regenerative Medicine: Cell & Gene Meeting on the Mesa
| Presenter: Date: Time: | Parag V. Meswani, PharmD, Chief Commercial Officer October 12, 2021 The company presentation will be available to view on-demand throughout the entirety of the conference. Please visit Cell & Gene Meeting on the Mesa for full information including registration. |
About Sio Gene Therapies
Sio Gene Therapies combines cutting-edge science with bold imagination to develop genetic medicines that aim to radically improve the lives of patients. Our current pipeline of clinical-stage candidates includes the first potentially curative AAV-based gene therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff diseases, which are rare and uniformly fatal pediatric conditions caused by single gene deficiencies. We are also expanding the reach of gene therapy to highly prevalent conditions such as Parkinson’s disease, which affects millions of patients globally. Led by an experienced team of gene therapy development experts, and supported by collaborations with premier academic, industry and patient advocacy organizations, Sio is focused on accelerating its candidates through clinical trials to liberate patients with debilitating diseases through the transformational power of gene therapies. For more information, visit www.siogtx.com.
Contacts:
Media
Josephine Belluardo, Ph.D.
LifeSci Communications
(646) 751-4361
jo@lifescicomms.com
info@siogtx.com
Investors and Analysts
Parag V. Meswani
Sio Gene Therapies Inc.
Chief Commercial Officer
investors@siogtx.com
FAQ
When will Sio Gene Therapies present at the Cantor Fitzgerald Global Healthcare Conference?
What is the date and time of Sio Gene Therapies' presentation at the Chardan Genetic Medicines Conference?
Who will represent Sio Gene Therapies at the Cell & Gene Meeting on the Mesa?
What is the focus of Sio Gene Therapies?
Where can I find the webcast links for Sio Gene Therapies' presentations?
